6. Gilead Sciences

A rarity on our list, Gilead Sciences easily spent more on its pipeline in the first nine months of 2019 than it did on buybacks and dividends. (Gilead)

Company: Gilead Sciences
Revenue in 2019: $16.57 billion
Value of repurchased stock 2019: $1.64 billion
Value of repurchased stock 2018: $1.93 billion
Dividends paid 2019: $2.42 billion
Dividends paid 2018: $2.24 billion
*All figures are first- to third-quarter totals.

Few pharmas have been more open about their desire for a major acquisition than Gilead, which spent much of the year plugging holes in its executive team. Despite the hunt for a big pickup, Gilead aimed high on pipeline spending on the year at the expense of stock buybacks and shareholder dividends. 

Gilead spent $1.64 billion on buybacks in the first nine months of 2019, about $290 million less than what it spent during the same time period in 2018. In terms of dividends, Gilead ponied up $2.42 billion in 2019 compared with a slightly lower $2.24 billion the year before. 

For 2019, at least, Gilead ranked as one of the rare drugmakers on the list that actually spent more on R&D than shareholder benefits, with $7.21 billion shelled out in the first three quarters. The year before, the drugmaker spent $3.07 billion on its pipeline during the same time frame.

With its 2019 buybacks, Gilead is still chipping away at a $12 billion share repurchase program its board authorized back in the first quarter of 2016, according to an SEC filing. As of Sept. 30, Gilead still had $3.5 billion in authorized buybacks remaining under that program. 

RELATED: Gilead elevates M&A architect Dickinson to CFO. Could more deals be next?

6. Gilead Sciences

Suggested Articles

The big names always turn up near the top of yearly sales rankings and this year is no different. Many companies on this list have faced big patent losses in…

This year looks like the end of the line for some of the biggest brands in the pharma industry.

Despite advances in life sciences and the corporate world, professional women still face numerous hurdles, even those at the top of their fields.